Paternal Metformin Use Does Not Increase Risk for Congenital Malformations
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 17, 2024 -- Paternal metformin use during the period of sperm development is not associated with an increased risk for congenital malformations in offspring, according to a study published online Oct. 16 in The BMJ.
Lin-Chieh Meng, from the National Taiwan University, and colleagues examined the association between paternal metformin use and the risk for congenital malformations in offspring in a population-based cross-sectional study. Participants included 619,389 offspring in the Norwegian cohort during 2010 to 2021 and 2,563,812 in the Taiwanese cohort during 2004 to 2018.
Paternal data on metformin use during the period of sperm development were available for 2,075 offspring in Norway and 15,276 in Taiwan. Of these offspring, 5.0 and 3.4 percent in Norway and Taiwan, respectively, had congenital malformations. The researchers found that in an unadjusted analysis, the risks for any congenital malformation associated with paternal metformin use were increased; with increasing control of confounding, the risk was attenuated. The relative risks of any malformations in association with paternal metformin use were 1.29 (95 percent confidence interval [CI], 1.07 to 1.55) and 1.08 (95 percent CI, 0.99 to 1.17) in Norway and Taiwan, respectively, in an unadjusted analysis, and 1.20 (95 percent CI, 0.94 to 1.53) and 0.93 (95 percent CI, 0.80 to 1.07), respectively, in an analysis restricted to fathers with type 2 diabetes mellitus.
"These results provide reassurance and can assist clinicians in making informed treatment decisions when selecting metformin in the treatment of type 2 diabetes mellitus among men who are planning a family," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Female PCPs Have Equal/Better Quality Outcomes Than Male PCPs
TUESDAY, May 20, 2025 -- Female primary care physicians (PCPs) in value-based payment models have equal or better quality outcomes and higher earning than their male counterparts...
Accurate Risk Prediction Model Developed for Pediatric Pneumonia
TUESDAY, May 20, 2025 -- An accurate risk prediction model has been developed for children younger than 14 years with community-acquired pneumonia (CAP), according to a study...
Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk
TUESDAY, May 20, 2025 -- Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women is a risk factor for preterm birth, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.